Imaging of Tumor Metabolism Using Positron Emission Tomography (PET)
Standard
Imaging of Tumor Metabolism Using Positron Emission Tomography (PET). / Apostolova, Ivayla; Wedel, Florian; Brenner, Winfried.
In: Recent Results Cancer Res, Vol. 207, 26.08.2016, p. 177-205.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Imaging of Tumor Metabolism Using Positron Emission Tomography (PET)
AU - Apostolova, Ivayla
AU - Wedel, Florian
AU - Brenner, Winfried
PY - 2016/8/26
Y1 - 2016/8/26
N2 - Molecular imaging employing PET/CT enables in vivo visualization, characterization, and measurement of biologic processes in tumors at a molecular and cellular level. Using specific metabolic tracers, information about the integrated function of multiple transporters and enzymes involved in tumor metabolic pathways can be depicted, and the tracers can be directly applied as biomarkers of tumor biology. In this review, we discuss the role of F-18-fluorodeoxyglucose (FDG) as an in vivo glycolytic marker which reflects alterations of glucose metabolism in cancer cells. This functional molecular imaging technique offers a complementary approach to anatomic imaging such as computed tomography (CT) and magnetic resonance imaging (MRI) and has found widespread application as a diagnostic modality in oncology to monitor tumor biology, optimize the therapeutic management, and guide patient care. Moreover, emerging methods for PET imaging of further biologic processes relevant to cancer are reviewed, with a focus on tumor hypoxia and aberrant tumor perfusion. Hypoxic tumors are associated with poor disease control and increased resistance to cytotoxic and radiation treatment. In vivo imaging of hypoxia, perfusion, and mismatch of metabolism and perfusion has the potential to identify specific features of tumor microenvironment associated with poor treatment outcome and, thus, contribute to personalized treatment approaches.
AB - Molecular imaging employing PET/CT enables in vivo visualization, characterization, and measurement of biologic processes in tumors at a molecular and cellular level. Using specific metabolic tracers, information about the integrated function of multiple transporters and enzymes involved in tumor metabolic pathways can be depicted, and the tracers can be directly applied as biomarkers of tumor biology. In this review, we discuss the role of F-18-fluorodeoxyglucose (FDG) as an in vivo glycolytic marker which reflects alterations of glucose metabolism in cancer cells. This functional molecular imaging technique offers a complementary approach to anatomic imaging such as computed tomography (CT) and magnetic resonance imaging (MRI) and has found widespread application as a diagnostic modality in oncology to monitor tumor biology, optimize the therapeutic management, and guide patient care. Moreover, emerging methods for PET imaging of further biologic processes relevant to cancer are reviewed, with a focus on tumor hypoxia and aberrant tumor perfusion. Hypoxic tumors are associated with poor disease control and increased resistance to cytotoxic and radiation treatment. In vivo imaging of hypoxia, perfusion, and mismatch of metabolism and perfusion has the potential to identify specific features of tumor microenvironment associated with poor treatment outcome and, thus, contribute to personalized treatment approaches.
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Magnetic Resonance Imaging
KW - Metabolic Networks and Pathways
KW - Molecular Imaging
KW - Neoplasms
KW - Positron Emission Tomography Computed Tomography
KW - Positron-Emission Tomography
KW - Radiopharmaceuticals
KW - Tumor Microenvironment
KW - Journal Article
KW - Review
U2 - 10.1007/978-3-319-42118-6_8
DO - 10.1007/978-3-319-42118-6_8
M3 - SCORING: Journal article
C2 - 27557539
VL - 207
SP - 177
EP - 205
JO - Recent Results Cancer Res
JF - Recent Results Cancer Res
SN - 0080-0015
ER -